CCM
ACHN

Camber Capital Management’s Achillion Pharmaceuticals ACHN Stock Holding History

Camber Capital Management’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-3,250,000
Closed -$32.4M – 48
2014
Q3 		$32.4M Sell
3,250,000
-2,550,000
-44% -$23.7M 3.05% 14
2014
Q2 		$43.9M Buy
+5,800,000
New +$23.1M 2.88% 12

Other funds holding ACHN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Camber Capital Management's ACHN Position: Q4 2014 in Review

Camber Capital Management sold out of Achillion Pharmaceuticals (ACHN) in Q4 2014, closing a stake of 3,250,000 shares — an estimated $32.4M sold.

Camber Capital Management first reported a position in ACHN in Q2 2014 and held it in 2 quarters. The position peaked at $43.9M in Q2 2014. 179 funds tracked by Wall St. Rank hold ACHN as of Q4 2014.

  • Camber Capital Management reported no remaining Achillion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Camber Capital Management sold 3,250,000 Achillion Pharmaceuticals shares in Q4 2014, an estimated $32.4M.
  • Camber Capital Management first reported a position in Achillion Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Camber Capital Management's Achillion Pharmaceuticals position peaked at $43.9M in Q2 2014.
  • 179 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2014.

Based on Camber Capital Management's 13F filing for Q4 2014, filed 13 Feb 2015.